On a per-share basis, the
The results missed
The genome editing company posted revenue of
For the year, the company reported that its loss widened to
Editas shares have fallen 24% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a
Automated Insights, source